|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
900 Camp St, New Orleans, Louisiana 70130, US
|
|
Revolo Biotherapeutics | 692 followers on LinkedIn. Analyze | Reset | Revolutionize | Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key molecule in immune function and is in clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is in clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.
|
Revolo Biotherapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Revolo Biotherapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Revolo Biotherapeutics customer service number in your country click here to find.
Jonathan Rigby is the CEO of Revolo Biotherapeutics. To contact Jonathan Rigby email at [email protected] or [email protected]. Or you may call +1 510 589 3268
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.